Welcome to our dedicated page for Neoleukin Therapeutics news (Ticker: NLTX), a resource for investors and traders seeking the latest updates and insights on Neoleukin Therapeutics stock.
Neoleukin Therapeutics, Inc. (symbol: NLTX) is a cutting-edge biopharmaceutical company focused on the development of next-generation immunotherapies. Using advanced de novo protein design technology, Neoleukin creates synthetic proteins with specific pharmaceutical properties designed to treat cancer, inflammation, and autoimmune diseases.
In recent developments, Neoleukin has implemented a reverse stock split, approved by its stockholders at the 2023 Annual Meeting held on June 8, 2023, and executed by the Board on August 30, 2023. This reverse stock split reduces the number of shares of common stock from approximately 44,026,429 to about 8,805,285, while also adjusting the number of authorized shares from 100,000,000 to 20,000,000. While this adjustment affects all stockholders uniformly, it simplifies stock management without altering any stockholder’s ownership percentage, except for those receiving cash in lieu of fractional shares.
As of March 2023, Neoleukin restructured its operations to conserve capital. This strategic move was part of an overarching plan to streamline operations while focusing on its core competencies. The company continues to leverage its sophisticated computational methods to develop proteins with superior therapeutic benefits compared to native proteins. Neoleukin's innovation has positioned it as a leader in the biotechnology sector, providing advanced solutions for complex health challenges.
Furthermore, a proposed merger and its anticipated impacts on the company’s stock and listing on the Nasdaq Capital Market are key topics for investors. The merger is expected to result in a combined total of approximately 13,676,732 shares of outstanding common stock.
For more information, please visit the Neoleukin website or contact Neoleukin's investor relations and media teams at investors@neoleukin.com.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A pre-recorded presentation will be available on-demand starting March 9, 2021, at 7:00 am ET via the Neoleukin investors section of their website. Neoleukin specializes in de novo protein therapeutics, focusing on advanced immunotherapies for cancer and autoimmune diseases. Their lead candidate is NL-201, an agonist designed to enhance tolerability and efficacy.
Neoleukin Therapeutics, a biopharmaceutical company listed on NASDAQ under the ticker NLTX, announced that CEO Jonathan Drachman will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days on March 12, 2021, at 3 p.m. ET. A live audio webcast will be available on the company's investor website, along with an archived replay for 30 days post-event. Neoleukin focuses on creating next-generation immunotherapies using de novo protein design technology, with its lead candidate, NL-201, targeting improved efficacy and tolerability.
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) announced on January 7, 2021, that it received a clinical hold letter from the FDA regarding its IND application for the Phase 1 study of NL-201, its immunotherapeutic candidate. The FDA's hold requires Neoleukin to develop a new assay for accurately measuring protein dosage and address additional non-hold related requests. CEO Jonathan Drachman expressed the company's commitment to respond swiftly and work closely with the FDA to resolve these issues.
NL-201 is designed to enhance cancer-fighting CD8 T cells and NK cells.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 14, 2021, at 4:30 p.m. ET. The presentation will include a live audio webcast and a subsequent Q&A session, accessible via the Neoleukin investor website. Neoleukin focuses on developing next-generation immunotherapies using de novo protein design technology, with its leading candidate, NL-201, aimed at enhancing the treatment of cancer and autoimmune diseases.
Neoleukin Therapeutics (NASDAQ:NLTX) has submitted an Investigational New Drug (IND) Application to the U.S. FDA for its lead immunotherapeutic candidate, NL-201, marking a significant milestone for the company. NL-201 is designed to mimic natural cytokines IL-2 and IL-15. The Phase 1 clinical trial, which will include up to 120 patients with relapsed or refractory solid tumors, aims to evaluate safety and anti-tumor activity. The study will be conducted in North America and Australia, with patient enrollment expected to commence soon.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The pre-recorded session will be available starting at 10 a.m. ET on November 23, 2020, via the investors section of Neoleukin's website. Neoleukin focuses on developing next-generation immunotherapies, leveraging innovative computational methods for protein design. Their lead candidate, NL-201, combines IL-2 and IL-15 agonists aimed at enhancing therapeutic benefits.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 4:40 p.m. ET. The event will be available via live audio webcast on the Neoleukin website, with an archived replay accessible for 30 days post-event. Neoleukin specializes in developing immunotherapies for cancer and autoimmune diseases using advanced computational methods to design innovative protein therapeutics. Their lead candidate, NL-201, aims to enhance efficacy by targeting specific receptors.
Neoleukin Therapeutics (NASDAQ: NLTX) reported financial results for Q3 2020, ending with $201.2 million in cash, up from $143.1 million at the end of 2019. The company is on track to submit an IND for NL-201, its lead immunotherapy candidate, by year-end 2020, and has submitted a CTN application in Australia. R&D expenses rose to $6.2 million, reflecting ongoing development, while general and administrative expenses decreased to $3.9 million. A gain of $7.8 million from the sale of Aquinox Canada contributed to a reduced net loss of $2.2 million, down from $59.1 million the prior year.
Neoleukin Therapeutics (NASDAQ:NLTX) announced a significant breakthrough in COVID-19 treatment with their de novo protein, NL-CVX1. Published in Science, the research demonstrates that NL-CVX1 effectively prevents SARS-CoV-2 infection in hamsters, maintaining survival after exposure to a lethal virus dose. This protein mimics the natural receptor for SARS-CoV-2, showing promise against viral mutations. The company is evaluating advancing this promising molecule to clinical trials in humans, showcasing their innovative protein design technology.
FAQ
What is the market cap of Neoleukin Therapeutics (NLTX)?
What does Neoleukin Therapeutics, Inc. do?
What is the recent reverse stock split about?
How does the reverse stock split affect stockholders?
Why did Neoleukin restructure its operations?
What are the notable technologies used by Neoleukin?
What is the impact of the proposed merger on Neoleukin's stock?
How can investors contact Neoleukin Therapeutics?
What is the significance of the de novo protein design technology?
Does the reverse stock split affect the company’s Nasdaq listing?
Where can I find more information about Neoleukin's recent developments?
